Thus the assessment of molecular receptors such as human epidermal growth factor receptor 2 (HER2) in breast cancer and epidermal growth factor receptor (EGFR) in non-small cell lung cancer is now routine to guide treatment regimens [8]. This evidence concerns the gene EGFR and breast carcinoma.